81 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
XLRN Acceleron Pharma Inc. $52 $2.39B N/A
Article Searches
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates http://www.zacks.com/stock/news/618288/biotech-stock-roundup-sldb-plunges-celg-gets-fda-nod-for-reblozyl-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-618288 Nov 13, 2019 - Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug http://www.zacks.com/stock/news/614169/celgene-acceleron-get-fda-nod-for-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-614169 Nov 11, 2019 - Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4303368-acceleron-pharma-inc-xlrn-ceo-habib-dable-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Nov 06, 2019 - Acceleron Pharma Inc. (NASDAQ:XLRN) Q3 2019 Earnings Conference Call November 6, 2019 10:00 AM ET Company Participants Ed Joyce - Director of Investor Relations Habib Dable - Chief Executive Officer K
Acceleron Pharma Inc (XLRN) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/11/06/acceleron-pharma-inc-xlrn-q3-2019-earnings-call-tr.aspx?source=iedfolrf0000001 Nov 06, 2019 - XLRN earnings call for the period ending .
Acceleron Pharma (XLRN) Reports Q3 Loss, Tops Revenue Estimates http://www.zacks.com/stock/news/606291/acceleron-pharma-xlrn-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-606291 Nov 06, 2019 - Acceleron (XLRN) delivered earnings and revenue surprises of -6.17% and 22.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for http://www.zacks.com/stock/news/592857/analysts-estimate-acceleron-pharma-xlrn-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-592857 Oct 30, 2019 - Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron Starts Enrollment in Phase III MDS Study on Imetelstat http://www.zacks.com/stock/news/559395/geron-starts-enrollment-in-phase-iii-mds-study-on-imetelstat?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-559395 Oct 11, 2019 - Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.
Geron's Imetelstat Gets Fast Track Status for Myelofibrosis http://www.zacks.com/stock/news/544470/gerons-imetelstat-gets-fast-track-status-for-myelofibrosis?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-544470 Oct 01, 2019 - Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More http://www.zacks.com/stock/news/524561/biotech-stock-roundup-biib-halts-ad-study-amgn-posts-positive-mm-drug-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-524561 Sep 18, 2019 - Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus http://www.zacks.com/stock/news/513224/biotech-stock-roundup-amgns-lung-cancer-candidate-alxns-deal-with-eidos-in-focus?cid=CS-ZC-FT-analyst_blog|stock_roundup-513224 Sep 11, 2019 - Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.

Pages: 123456...9

Page 1>